SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: crysball who wrote (796)5/9/1998 8:09:00 PM
From: yosi s  Read Replies (1) | Respond to of 1491
 
AS to cash flow any advances made to pars from boll will be taken against royalties.
PARS expenses are cost of bulk product and royalties to the person discovered Alrex and Lotemax.



To: crysball who wrote (796)5/10/1998 5:47:00 PM
From: Ariella  Read Replies (1) | Respond to of 1491
 
Dear Crysball:

You wrote << didn't you have a model which would address the question by Investor Lady on the revenue stream, based on on a set of assumptions about market penetration?

Was there consensus the royalty figure was 18% after some adjustments?>>

See March 1998 PARS posts 283 to 288 -- this is where the great debate began. My thinking is closer to David's position at this point.

Regards,
Ariella


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News